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Mesenchymal stem cells (MSCs) are adult stem cells that were initially isolated from bone marrow. However, subsequent research
has shown that other adult tissues also contain MSCs. MSCs originate from mesenchyme, which is embryonic tissue derived
from the mesoderm. These cells actively proliferate, giving rise to new cells in some tissues, but remain quiescent in others.
MSCs are capable of diﬀerentiating into multiple cell types including adipocytes, chondrocytes, osteocytes, and cardiomyocytes.
Isolation and induction of these cells could provide a new therapeutic tool for replacing damaged or lost adult tissues. However,
the biological properties and use of stem cells in a clinical setting must be well established before signiﬁcant clinical beneﬁts
are obtained. This paper summarizes data on the biological properties of MSCs and discusses current and potential clinical
applications.
1.Introduction
As t e mc e l li sa nu n d i ﬀerentiated cell with the capacity for
multilineage diﬀerentiation and self-renewal without senes-
cence. Totipotent stem cells (zygotes) can give rise to a full
viable organism and pluripotent stem cells (embryonic stem
(ES) cells) can diﬀerentiate into any cell type within in the
human body. By contrast, trophoblasts are multipotent stem
cellsthatcandiﬀerentiateintosome(e.g.,mesenchymalstem
cells (MSCs), hematopoietic stem cells (HSCs)), but not all,
cell types.
Adult tissues have speciﬁc stem cell niches, which supply
replacement cells during normal cell turnover and tissue
regeneration following injury [1–3]. The epidermis, hair,
HSCs, and the gastrointestinal tract all present good exam-
ples of tissues with niches that contribute stem cells during
normal cellular turnover [3]. The exact locations of these
stem cell niches are poorly understood, but there is growing
evidence suggesting a close relationship with pericytes [1,
4, 5]( Figure 1). MSCs have been isolated from adipose
tissue [6], tendon [7], periodontal ligament [8], synovial
membranes [9], trabecular bone [10], bone marrow [11],
embryonic tissues [12], the nervous system [13], skin [14],
periosteum [9], and muscle [15]. These adult stem cells were
once thought to be committed cell lines that could give
rise to only one type of cell, but are now known to have
a much greater level of plasticity [16, 17]. Despite the vast
variety of source tissues, MSCs show some common char-
acteristics that support the hypothesis of a common origin
[1, 18]. These characteristics are: ﬁbroblast like shape in
culture, multipotent diﬀerentiation, extensive proliferation
capacity, and a common surface marker proﬁle (e.g., CD34−,
CD45−(HSC markers), CD31− (endothelial cell marker),
CD44+, CD90+, and CD105+ (Table 1)). However, there is
no surface marker that uniquely deﬁnes MSCs.
The same general approaches are used to isolate all kinds
of MSCs, including the use of Dulbecco’s Modiﬁed Eagle
Medium (DMEM) to dissolve collagenase, digestion times
limited to a maximum of 1 hour at 37◦C, isolation of stem
cells as soon as possible following euthanasia, and the use
of culture medium at temperatures not lower than room
temperature [1].2 Stem Cells International
Figure 1: Double immunoﬂuorescence staining of microvessels in a mouse inguinal fat pad (paraﬃn embedded). CD34-positive (left;
secondary antibody Texas red)a n dα-smooth muscle actin-positive (α-SMA, middle; secondary antibody FITC) staining is shown. The cells
surrounding the microvessels are positive for both CD34 and α-SMA (right panel: marked with black arrow heads), suggesting a possible
relationship between pericytes and MSCs. Nuclei were counterstained with hematoxylin. Scale bars, 20μm.
Table 1: Surface marker expression proﬁles of main MSCs types.
MSCs CD marker expression∗
ASCs CD13+,C D 2 9 +,C D 4 4 +,C D 7 1 +,C D 9 0 +,
CD105/SH2 and SH3+,S T R O - 1 +.
BM-MSCs CD44+, CD105+, CD166+,C D 2 8 +,C D 3 3 +,
CD13+,H L Ac l a s sI +
ES
SSEA 3&4+,C D 9 0 +,C D 9 +, TRA-1-60+,
TRA-1-81+, GCTM2+, GCT343+, TRA-2-54+,
TRA-2-49+,c l a s sIH L A +
HSCs CD34+,C D 9 0 +
PDLSCs STRO-1+,C D 1 3 +,C D 2 9 +,C D 4 4 +,C D 5 9 +,
CD90+, CD105+
TB-MSCs CD73+,S T R O - 1 +, CD105+
SM-MSCs CD44+,C D 7 3 +,C D 9 0 +, CD105+
Periosteum-MSCs CD90+
M-MSCs CD34+,S c a 1 +
Dermal SSCs∗∗
CD105+,C D 9 0 +,C D 7 3 +,C D 2 9 +,C D 1 3 +,
CD44+CD59+,V C A M - 1 +,I C A M - 1 +,C D 4 9 +,
CD166+,S H 2 +,S H 4 +,E G F R +,P D G F R a +,
CD271+,S t r o - 1 +,C D 7 1 +, CD133+, CD166+
WJ-MSCs CD105+,C D 7 3 +,C D 9 0 +
∗MSCs are commonly negative for CD14, CD16, CD31, CD34, CD45, CD
56, CD61, CD62E, CD104, and CD106.
∗∗Thereisstillnoconsensusregardingthelocation,markers,andsubgroups
of human epidermal skin stem cells.
Numerous studies have been conducted by diﬀerent
researchers from diﬀerent scientiﬁc disciplines using stem
cells. However, the results are somewhat inconsistent, which
has led to a number of controversies in the literature. To
review all these controversies along with the underlying data
would be an overwhelming task; therefore, the aim of this
paper is to brieﬂy describe the biological properties of the
main types of MSCs and to discuss their potential clinical
applications.
2.Adipose-DerivedStemCells (ASCs)
ASCs were ﬁrst isolated by Zuk et al. [19]. ASCs can
diﬀerentiate into ectodermal and endodermal lineages, as
well as the mesodermal lineage [20]. ASCs can be obtained
from either liposuction aspirates or excised fat. Small
amounts of adipose tissue (100 to 200mL) can be obtained
under local anesthesia. One gram of adipose tissue yields
approximately 5,000 stem cells, whereas the yield from BM-
derived MSCs is 100 to 1,000 cells/mL of marrow [21].
On average, the yield of ASCs from processed lipoaspirate
comprises approximately 2% of nucleated cells [21]. In their
original study, Zuk et al. noted that ASCs express CD13,
CD29, CD44, CD71, CD90, CD105/SH2, SH3, and STRO-
1. In contrast, no expression of the hematopoietic lineage
markers CD14, CD16, CD31, CD34, CD45, CD 56, CD 61,
CD 62E, CD 104, and CD106 was observed [20]. Although
ASCs were only identiﬁed relatively recently, their ease of
harvest and abundance place them in a unique position
relative to other MSCs.
3. Bone Marrow-Derived-Stem
Cells(BM-MSCs)
BM-MSCs are a primitive population of CD34−, CD45−,
CD44+, CD105+, CD166+, CD28+, CD33+, CD13+ and HLA
class I+ cells [22]. The existence of precursor stromal cells
in bone marrow has long been known and these cells were
ﬁrst named Westen-Bainton cells [23]. It was Friedenstein
et al., who plated these cells and obtained colony forming
units in vitro for the ﬁrst time [24]. Studies by Castro-
Malaspina et al. [25], Fei et al. [26], and Song et al. [27]
supplied a better understanding of biological properties
of bone marrow stromal cells; such as their ﬁbroblast-like
morphology, and the lack of the basic characteristics of
endothelial cells and macrophages. Subsequent studies by
Chailakhyan and Lalykina [28], Ashton et al. [29], Patt et al.
[30], Owen [31], Bennett et al. [32], and revealed the in vitro
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cells. Two milestone studies documenting the multipotential
diﬀerentiation of BM-MSCs were published by Caplan [33]
and Pittenger et al. [34]. Currently, BM-MSCs are known
to diﬀerentiate into osteogenic, adipogenic, chondrogenic
and neural lineages [22, 35]. MSCs in the BM are thought
to generate and maintain the proper microenvironment for
HSCs by secreting cytokines and growth factors [22, 35,
36]. The estimated frequency of BM-MSCs is 1 in 3.4 ×
104 cells, the lowest among the known sources of MSCs
[22]. Yoshimura et al. [37] showed that rat BM-MSCs were
the least potent stem cell in terms of colony number per
nucleated cell, colony number per adherent cell, and cell
number per colony. Gronthos et al. [38] suggested two
possible origins for BM-MSCs: vascular smooth muscle cells
or pericytes (since BM-MSCs express α-SMA and respond to
PDGF) (Figure 1) or endosteal cells.
The method used to isolate BM-MSCs is diﬀerent from
that used for other MSCs. This is because little extracellular
matrix is present in BM; therefore, instead of collage-
nase digestion, gentle mechanical disruption by repeated
pipetting is used to create a suspension of stromal and
hematopoietic cells. Upon plating, BM-MSCs rapidly adhere
to culture dishes, whereas nonadherent hematopoietic cells
are washed away by medium changes [5]. The resultant BM-
MSC population is highly heterogeneous and isolating pure
stem cells from this primary isolate is diﬃcult due to the lack
of unique cell surface markers [5].
4. Periodontal Ligament-Derived Stem
Cells(PDL-SCs)
The periodontium comprises the gingiva, periodontal lig-
ament, alveolar bone, and cementum. The periodontal
ligament, which connects the alveolar bone to the root
cementum and suspends the tooth in its alveolus, contains
stem cells with the potential to form periodontal structures
such as cementum and ligament [39]. The periodontal
ligament contains ﬁbroblasts, cementoblasts, osteoblasts,
macrophages, undiﬀerentiated ectomesenchymal cells, cell
rests of Malassez, and vascular and neural elements that are
capable of generating and maintaining periodontal tissues
[40]. PDL-SCs express the MSC-associated markers CD13,
CD29, CD44, CD59, CD90, and CD105, as well as STRO-
1[ 41]. Similar to other MSCs, PDL-SCs show osteogenic,
adipogenic, and chondrogenic characteristics under deﬁned




by Beresford et al. [45], MacDonald et al. [46], Wergedal
and Baylink [47], and Robey and Termine [48]. Tuli et
al. isolated a CD73+,S T R O - 1 +, CD105+, CD34−, CD45−,
CD144− cell population from human bone fragments. These
cells exhibited stem cell-like characteristics such as a stable
undiﬀerentiated phenotype, and the ability to proliferate
extensively and diﬀerentiate into osteoblastic, adipogenic
and chondrogenic lineages [10, 49]. Thus, these cells were
named human trabecular bone mesenchymal progenitor
cells [10]. In another study, Sottile et al. demonstrated that
cultures of TB-MSCs are equivalent to cultures of bone
marrow-derived stem cells in terms of proliferation and
multipotent diﬀerentiation capabilities [49]. Since the ﬁrst
description, in vitro secondary culture of cells derived from
human trabecular bone have been used to examine implant-
bone interactions and osteoblast biology [10, 49].
6. SynovialMembrane-DerivedStem
Cells(SM-MSCs)
The synovial membrane is a source of relatively homoge-
neous, ﬁbroblast-shaped, multipotent MSCs [9, 50]. The
protocol used for isolating MSCs and ﬁbroblasts from syn-
ovial membranes is the same [51]; however, SM-MSCs have
a phenotype very similar to that of type B synoviocytes, that
is, they contain characteristic lamellar bodies and express
surfactantproteinA,ahydrophilicproteinalsofoundinlung
surfactant [50]. Fluorescent-activated cell sorting (FACS)
analysis revealed that SM-MSCs are CD34−, CD45−, CD31−,
CD14− and CD44+, CD73+, CD90+, CD105+,ap h e n o t y p e
similar to that of MSCs derived from other tissues [9, 51,
52].SM-MSCsareimmunosuppressiveanddiﬀerentiateinto
chondrogenic, adipogenic, and, to a lesser extent, osteogenic
and myogenic lineages [9, 51]. Yoshimura et al. found that
rat SM-MSCs were superior to bone-marrow-, adipose
tissue-, periosteum-, and muscle-derived stem cells in terms
of colony number per nucleated cell, colony number per
adherent cell, and cell number per colony [37]. In particular,
SM-MSCs showed the highest potential for chondrogenic
diﬀerentiation, making them an ideal MSC type for cartilage
regenerationstudiesinratmodels[37].Similarﬁndingswere
reported [52] for human MSCs derived from bone marrow,
synovium, periosteum, skeletal muscle, and adipose tissue.
Synovium can be harvested arthroscopically with a relatively
lowlevelofinvasiveness.Donorsitemorbidityisalsolowdue
to the high regenerative capacity of the synovial membrane
[52].
7. Periosteum-Derived Stem Cells (P-MSCs)
P-MSCs are essential for bone repair and a reduction in the
availability of P-MSCs leads to a signiﬁcant decrease in
the healing capacity of bone [53]. Yoshimura et al. [37]
found that rat P-MSCs showed the highest osteogenic
diﬀerentiationpotential.TheosteogenicpotentialofP-MSCs
is further supported by Perka et al. [54], who used P-MSCs
seeded into polyglycolid-polylactid acid scaﬀolds to treat
ulnar defects in New Zealand white rabbits. P-MSCs share
a common surface marker expression proﬁle with other
MSCs; thus, they are CD11−, CD45−, and CD90+. Johnstone
et al. [55] successfully repaired an experimental cartilage
defect using P-MSCs, thereby demonstrating their capacity
to diﬀerentiate into diﬀerent cell lineages.4 Stem Cells International
8. Muscle-DerivedStem Cells and Satellite
Cells(M-MSCs)
Postnatal skeletal muscle tissue, similar to bone marrow,
contains two diﬀerent types of stem cells, M-MSCs and
satellite cells, both of which can function as muscle pre-
cursors [56, 57]. Satellite cells are unipotent cells that
originate from a population of muscle progenitors during
embryogenesis [58] .T h eo r i g i no fs a t e l l i t ec e l l si sa m o n g
the most thoroughly studied aspects of morphogenesis.
Segmental mesodermal structures on each side of the neural
tube give rise to the skeletal muscle of the body [58]. A
number of studies show that satellite cells from the trunk
and extremities originate from the central and lateral der-
momyotome, respectively, while those in the head originate
from head mesoderm. Satellite cells in an adult constitute
a small fraction of cells (2–7%) relative to the number of
cells that fused to generate a particular muscle ﬁber [58],
but are necessary for postnatal muscle regeneration [13, 56,
57]. A small subpopulation of satellite cells are stem cells
by deﬁnition, since they possess an inherent capacity for
self-renewal and can give rise to daughter cells [56, 57].
Satellite cells maintain a close spatial relationship with the
muscles from which they derive, occupying the grooves
or depressions between the basal lamina and sarcolemma,
which suggests that a local source, rather than a distant one,
produces the satellite cells [56, 58]. The hallmark genes for
satellite cells are Pax 7 and Pax 3, with the latter only being
expressed by a subset of satellite cells [58].
M-MSCs not only act as muscle precursors but also give
rise to a variety of other cell types, including hematopoietic
cells [56, 59, 60]. M-MSCs have a high proliferation and
self-renewal capacity and are CD34+,S c a 1 +, CD45−,a n dc -
Kit− [57].M-MSCsarecapableofdiﬀerentiatingintoskeletal
muscle cells both in vivo and in vitro and spontaneously
expressmyogenicmarkers.Takentogether,thesedatasuggest
that M-MSCs are derived from skeletal myoﬁbers [57].
However, a recent study by McKinney-Freeman et al. [61]
suggests that M-MSCs are, in fact, HSCs residing in skeletal
muscle rather than transdiﬀerentiated myogenic cells.
9. SkinStem Cells(SSCs)
MSCs are found in the dermal layer of skin. Toma et al.
[14] isolated a multipotent, nestin and ﬁbronectin positive,
adult stem cell population from rodent skin. In a recent
study by Vishnubalaji et al. mesenchymal stem cells isolated
from human dermal skin were positive for CD105, CD90,
CD73, CD29, CD13, and CD44 and were negative for
endothelialandhematopoieticlineagemarkersCD45,CD34,
CD31, CD14, and HLA DR [62]. Shi and Cheng [63]a d d e d
that MSCs from newborn dermis were also positive for
CD59, vascular cell adhesion molecule-1 (VCAM-1), and
intercellular adhesion molecule-1 (ICAM-1). Other surface
markers that are reported to be expressed by SSCs are
CD49, CD166, SH2, SH4, EGFR, PDGFRa [64], CD271
[65], Stro-1 [66], CD71, CD133, and CD166 [67]. SSCs
can diﬀerentiate into adipocytes, osteoblast, chondrocyte,
neuron, hepatocyte, and insulin producing pancreatic cells
[62].
10. Wharton’s Jelly Stem Cells (WJ-MSCs)
WJ-MSCs are obtained from Wharton’s jelly of umbilical
cord [68]. Compared to BM-MSCs, WJ-MSCs exhibit a
higher expression of undiﬀerentiated human embryonic
stem cell (hES) markers like NANOG, DNMT3B, and
GABRB3[69]; thus, they are more primitive then other types
of MSCs and easy to obtain with no ethical considerations
[70]. They express the typical MSCs markers: CD105, CD73,
and CD90 and negative for CD45, CD34, CD14, CD19, and
HLA-DR [70]. UC-MSCs can be induced into endothelial
cells, adipogenic, osteogenic, chondrogenic, neurogenic lin-
eages [70], insulin producing cells [71], and hepatocyte-like
cells [72].
11.MiscellaneousStemCells
MSCs reside in essentially all adult tissues [73]. In addition
to the MSCs discussed in this paper, stem cells have been
isolated from liver, perichondrium, pancreas, hair follicles,
intestinal epithelium, placenta, and amniotic membranes.
12.ClinicalUse andFuturePerspectives
Using stem cells alone, or in combination with scaﬀolds, to
regenerate organs or tissues is a quite new idea. The type
of cell and the route of administration are both equally
important for the success of such stem cell treatments. ES
cellsshowthegreatestpotentialfortissueregenerationowing
to their totipotency. Barberi et al. [74], Benninger et al. [75],
and Chiba et al. [76] reported that ES cell-derived neurons
injected into the mouse brain were successfully integrated
and corrected the phenotype of a neurodegenerative disease.
However, the clinical use of ES cells is encumbered by ethical
considerations.
In a comparative study of human MSCs obtained from
various tissues, Sakaguchi et al. [52] demonstrated that
SM-MSCs and ASCs show superior adipogenic potential,
whereas BM-MSCs, SM-MSCs, and P-MSCs show superior
osteogenic potential. ASCs are a relatively new subtype of
MSC that can be obtained by less invasive methods and in
larger quantities than other MSCs [19]. ASCs also have a
multilineage diﬀerentiation capacity similar to that of BM-
MSCs and can easily be grown in standard tissue culture
conditions [19]. The above data provide a useful guide for
selecting the appropriate type of MSC for use in clinical
regenerative medicine.
ThegrowthfactorsecretomeofhMSCswascharacterized
by Haynesworth et al. [36]. The secretory activity of hMSCs
helps them to establish a regenerative microenvironment at
sites of tissue injury [2]. Nevertheless, there is no evidence
for a biologically signiﬁcant eﬀect of systemic MSC injection
[77]. Tissue engineering oﬀers a number of scaﬀolds to
improve the outcomes of stem cell applications, enabling
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be used in a number of diﬀerent ways: (i) scaﬀolds can
be seeded with MSCs in vitro and implanted after a short
incubation period, (ii) loaded scaﬀolds can be kept in
diﬀerentiation medium for1–2 weeks beforeimplantation to
stimulate MSCs to diﬀerentiate into a speciﬁc lineage, or (iii)
MSCs can be induced into a speciﬁc lineage before seeding
intothescaﬀoldandthescaﬀoldimplantedshortlythereafter
[78]. The organization of the cells on the scaﬀolds and
formation of vascular channels can be induced using speciﬁc
growth factors, but this requires an adequate understanding
of the paracrine mechanisms controlling tissue growth [16].
These complex paracrine mechanisms have attracted a great
deal of interest in recent years, but are still not fully
understood.
Thetissuesthatcanreadilybeengineeredusingstemcells
are skin [79], cornea [80], bone [81], blood vessels [82],
cartilage [83], dentin [84], heart muscle [85], liver [86],
pancreas [87], nervous tissue [88], skeletal muscle [89],
and tendon [90, 91]. Given the experimental data collected
thus far, tissue engineered cardiac muscle [16], bone [81],
and cartilage [92] seem to be the most suitable candidates
for routine clinical application. BM-MSC transplantation
improves cardiac function in patients with myocardial
infarction and no side eﬀects have been reported [93]. An
alternative method for MSC transplantation is the cell sheet
method [94]. Osiris Therapeutics in the USA launched a
p hase1saf etytrialo fau t olog oushMSCs,whic har ed eli v e r ed
on a hydroxyapatite implant for alveolar ridge regeneration
prior to dental implantation [92]. The same tissue engi-
neering techniques have been applied to cartilage tissue
engineering, enabling our group to construct ear cartilage
in vitro [92]. MSCs have also been employed for cartilage
regeneration in rheumatoid arthritis and osteoarthritis, but
the results were not satisfactory [95]. Complete in vivo
restoration of cartilage has not yet been achieved.
A search using NIH database (http://clinicaltrials.gov/)
yielded 218 ongoing clinical trials utilizing MSCs. The main
indications are multiple sclerosis, type I diabetes, GVHD,
inﬂammatory bowel disease, cardiac ischemic diseases, cere-
bral vascular diseases, various autoimmune connective tissue
disorders, spinal cord injury, ischemic extremity diseases,
liver diseases and, bone and cartilage defects. A potential
clinical use of MSCs is related to their anti-inﬂammatory
and immunosuppressive eﬀects. The results of phase III and
phase II clinical trials conducted by Osiris Therapeutics and
Le Blanc et al., respectively, suggested that BM-MSCs block
acute graft versus host disease (GVHD) without any side
eﬀects [96, 97]. An additional clinical trial carried out by
Osiris Therapeutics showed improvements in the symptoms
of the inﬂammatory bowel disease (Crohn’s disease) by at
least 100 points on the Crohn’s disease activity index [96]. A
phase I study by Duijvestein et al. yielded similar results [98].
There a number of studies reporting the usefulness of MSCs
in the treatment of autoimmune disorders such as rheumatic
diseases, autoimmune encephalomyelitis, multiple sclerosis,
andsystemiclupuserythematosus(SLE)[99–103].MSCsare
believed to exhibit their immunomodulatory eﬀects through
soluble factors [104, 105]. In the light of the data obtained
from experimental studies some clinical trials were launched
andaconsensusontheuseofMSCsformultiplesclerosishas
already been established [106, 107]. Another clinical use of
MSCs is for the immune-modulation following solid organ
transplants [108].
Once considered rather futuristic, in utero human HSC
transplantation has become technically feasible and may
be the gold standard for treating congenital hematological
diseases and enzyme deﬁciencies [109].
Muscular dystrophies constitute a special group of
disorders that may also be treated with MSCs. Muscular
dystrophy deﬁnes a heterogeneous group of muscular dis-
orders characterized by deﬁcient production of dystrophin,
which links the actin cytoskeleton to the extracellular
matrix protein laminin, thereby protecting the muscle ﬁbers
from contraction induced damage [56]. Loss of dystrophin
leads to damage to the sarcolemma that in turn leads to
continued activation of satellite cells [56]. Repeated cycles of
degeneration and regeneration overwhelm the regenerative
capacity of the satellite cells, causing muscular weakness
as the disease progresses [56]. Stem cell transplantation to
restore the defective dystrophin is a promising treatment
modality [56]. However, there are conﬂicting reports regard-
ing the success of stem cell transplantation. In a study
performed to investigate whether HSCs can participate in
muscle regeneration, transplanted BM-HSCs were poorly
e n g r a f t e di nd y s t r o p h i cm u s c l e sa n dr e s t o r e dd y s t r o p h i n
expression only in an average of 0.23% of ﬁbers [110]. By
contrast, Qu-Petersen et al. [57] reported successful M-MSC
transplantation into mdx mice, even though the animals
were not immunosuppressed. The number of M-MSCs
found in the mdx muscle was stable over a 90-day period.
Interestingly, the results could not be reproduced using
satellite cells. This was attributed to the lack of expression
of MHC-I by M-MSCs, thereby granting them immune-
privilege, and to the higher self-renewal ability of M-MSCs.
To date, clinically useful levels of stem cell engraftment to
muscle tissue have not been reported [56]. Alternatively,
stem cells could be used to introduce genes into muscle
tissue to increase the production of deﬁcient proteins [5, 56].
MSCs can easily be obtained from patients, manipulated
genetically, expanded to obtain an adequate number of cells
and, ﬁnally, reintroduced into body [5]. This treatment
schema bypasses the risks associated with virus vectors [5].
However, the current level of gene transduction into MSCs,
the level of engraftment of MSCs to the target tissues, and
the sustainability of the desired gene expression are the main
issues that need to be improved if this is to become an
eﬀective treatment modality [5]. Furthermore, genetically
modiﬁed MSCs may not necessarily incorporate into target
tissues to correct the defective gene, but may also reside in
the connective tissue acting as minipumps that secrete the
gene product [5]. Methods to increase the eﬃciency of gene
therapy are currently ongoing.
The current problems with the clinical application of
MSCs are insuﬃcient engraftment of the stem cells to target
tissues, inadequate vascularization of tissue engineered con-
structs to ensure long term viability, the possibility of induc-
ing teratomas [16], and immunogenic reactions directed
against allogeneic cells [16]. In addition, the expression of6 Stem Cells International
one or more proteins speciﬁc for a certain cell lineage in
vitro does not necessarily mean that MSCs bearing these
proteins will exhibit the functions of this speciﬁc cell type
properly in vivo [111]. Moreover, the study by Terada et al.
raises doubts regarding whether in vivo transdiﬀerentiation
of transplanted MSCs actually occurs, or is the result of cell
fusionmisinterpretedastransdiﬀerentiation[92,112].Safety
issues regarding the MSCs transplantation have been largely
solved, particularly with autologous transplants; however,
sustained curative beneﬁt has not been established yet.
Increasingly, new stem cell types are being explored and
there are a considerable number of clinical phase I/II trials as
mentioned previously. Even though it is too early to predict
the outcome of these trials at present, early observations of
patients indicate promising results without any signiﬁcant
side eﬀects [113]. Transfer of xenogenic proteins into human
body along with the MSCs is another potential problem in
clinical use of MSCs. Main source of xenogenic contamina-
tion is the fetal bovine serum (FBS) used as a supplement
for in vitro expansion of MSCs. FBS should be replaced with
an autologous or xeno-free supplement in the clinical setting
[114, 115]. As new information is gathered from future
studies, our understanding of the complex diﬀerentiation
mechanisms of stem cells will help us to solve current
problems and achieve crucial improvements in the use of
stem cells for clinical applications.
13. Conclusion
There is no doubt that stem cell therapy is a promising
treatment for the regeneration of damaged human tissues.
Some successful clinical results have been reported by a
number of groups. However, the methods of administration
need to be improved before a broader spectrum of clinical
applications can be successfully achieved. Currently, the
possibility of obtaining a signiﬁcant clinical outcome after
systemic administration of MSCs without speciﬁc targeting
seems remote.
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